SHALBY Shalby Q1 FY26 results (Apr–Jun 2025) and concall
Shalby Limited delivered a strong Q1 FY26 with record consolidated revenue crossing INR300 crores and significant QoQ EBITDA recovery. The standalone hospital business showed healthy ARPOB growth, and the MedTech implant business demonstrated robust YoY revenue growth and turned EBITDA positive on a standalone basis. However, overall occupancy saw a YoY decline, and the Sanar hospital's performance was impacted by external factors, though management expects a rebound.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 268 | 276 | 265 | 296 |
| EBITDA | 33 | 34 | 21 | 42 |
| Net profit | 2 | -3 | -12 | 8 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
